Akebia Therapeutics (AKBA) FCF Margin Growth (3y) (2020 - 2026)
Akebia Therapeutics (AKBA) FCF Margin Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 213.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 2,102.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 180.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 1,592.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -291.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -2,476.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 1,604.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | 538.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 538.00 |
| Mar 31, 2026 | 986.00 |
| Dec 31, 2025 | 14,788.00 |
| Sep 30, 2025 | -91.00 |
| Jun 30, 2025 | 5,504.00 |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | -4,950.00 |
| Sep 30, 2024 | 10,486.00 |
| Jun 30, 2024 | 9,344.00 |
| Mar 31, 2024 | 7,118.00 |
| Dec 31, 2023 | 13,283.00 |
| Sep 30, 2023 | 18,892.00 |
| Jun 30, 2023 | -2,988.00 |
| Mar 31, 2023 | 5,034.00 |
| Dec 31, 2022 | 18,136.00 |
| Sep 30, 2022 | -3,599.00 |
| Jun 30, 2022 | 11,921.00 |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | 18,185.00 |
| Sep 30, 2021 | -9,929.00 |